This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Aging/ Geriatrics  • Neurology  • Dementias  • Neurogenetics  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Bridget M. Kuehn

JAMA. 2008;300(4):379-380.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The US Food and Drug Administration (FDA) is warning physicians that using conventional antipsychotic drugs to treat elderly patients with dementia may increase the risk of death in these patients. In 2005, the agency warned of similar risks associated with newer atypical antipsychotic drugs.

Antipsychotic medications pose particular health risks to elderly patients with dementia. (Photo credit: Lauren Shear/www.sciencesource.com)

Under new authority granted to the agency by the Food and Drug Administration Amendments Act of 2007, the agency is requiring manufacturers of conventional antipsychotics (which include prochlorperazine, haloperidol, loxapine, thioridazine, molindone, thiothixene, pimozide, fluphenazine, trifluoperazine, chlorpromazine, and perphenazine) to add a boxed warning to the labels of these drugs notifying physicians that using conventional antipsychotics to treat behavioral problems in elderly patients with dementia is associated with an increased risk of death. Previously, the agency could only request and negotiate for such a change.

The . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Limited Effectiveness of Atypical Antipsychotics in Alzheimer Disease
JWatch Psychiatry 2008;2008:2-2.
FULL TEXT